Posts

Circular RNA what and why?

Image
Circular RNA in Ovarian Cancer Study Reference: Preclinical Research Feature; Cell Death Discovery / Bioengineer. org (2026) When patients use search engines or artificial intelligence tools, they frequently encounter complex molecular terms like circular RNA; without clinical context, this can lead to confusion or misplaced hope regarding emerging therapies. While circulating DNA is well recognised as an active cancer marker, circular RNA, a robust, deformed variant of normal RNA, causes tumour progression. Because circular RNA possesses an exceptionally stable structure that extends its half-life, studies show it can influence ovarian cancer under hypoxic conditions by blocking normal gene regulation and promoting angiogenesis. Although still in early preclinical stages, understanding these molecular pathways helps nurses to guide patients through novel biomarker discoveries. Key Points Structural Stability: Unlike linear messenger RNA, circular RNAs are closed-loop stru...
Post a Comment
Read more

Is screening the BRCA +ve cost-effective?

Image
Should BRCA-Positive Women Undergo Regular Ovarian Cancer Screening? Study Reference: Review Article / Clinical Debate; Cancer Network (2026) Women carrying BRCA mutations face an elevated risk of developing ovarian cancer;  the National Comprehensive Cancer Network (NCCN) in the US recommends screening every 6 months, using imaging and serology . However, this intensive approach is costly and consumes limited resources.  Dr Beth Karlan from Cedars-Sinai strongly supports routine screening , arguing that early detection promotes survival and citing incomplete studies with promising results . Conversely, Dr Michael Birrer from Boston opposes routine screening , emphasising that CA-125 serology is notoriously unreliable in younger women , and noting that because most high-grade serous cancers originate in the fallopian tubes , our understanding of the natural history of the disease remains incomplete . Key Points Elevated Genetic Risk: Women harbouring BRCA pathogenic varia...
Post a Comment
Read more

Why long-term survivors die

Image
What Do Long-Term Survivors of Ovarian Cancer Die Of? Study Reference: Population-Based Cohort Study | BMC Cancer (2026) ; Information about causes of death among apparent long-term survivors of ovarian cancer remains scarce.  Using UK Biobank data, this study examined 920 long-term survivors, measuring late mortality alongside associated genetic, socioeconomic, and biochemical factors. The findings reinforce previous understandings that despite passing the 5-year survival milestone, the majority of these women ultimately succumb to recurrent ovarian cancer. However, the study also uncovered critical competing risks: obese individuals and smokers face a significantly elevated risk of dying from cardiovascular disease;  women with underlying genetic DNA repair defects carry a higher likelihood of developing and dying from a second primary cancer. Key Points Primary Cause of Death: Despite achieving 5-year survival, ovarian cancer remains the predominant cause of la...
Post a Comment
Read more

Calculated benefit of risk reduction surgery

Image
Long-Term Benefits of Bilateral Salpingo-Oophorectomy Study Reference: Prospective Cohort Study; JAMA Surgery (2026) Many women with a family history of ovarian cancer or a confirmed BRCA1 or BRCA2 pathogenic variant elect to undergo risk-reducing surgery to manage their lifetime cancer risk. Looking at calculated outcomes from a large prospective cohort of 5,713 women, this study measures the protective benefits of bilateral salpingo-oophorectomy (BSO). The findings demonstrate substantial reductions in both ovarian cancer incidence and overall mortality; this evidence provides clear guidance for clinicians and women navigating prophylactic surgical decisions. Key Points Substantial Risk Reduction: Bilateral salpingo-oophorectomy lowers the risk of ovarian, fallopian tube, and primary peritoneal cancers by approximately 80%. Overall Survival Advantage: Prophylactic surgery significantly reduces all-cause mortality among women carrying BRCA pathogenic variants. Critical Importance o...
Post a Comment
Read more

Prepare beforehand

Image
The Case for Prehabilitation in Advanced Ovarian Cancer Study Reference: Gynecologic Oncology (2026)   Prehabilitation, a targeted program combining optimised nutrition, physical exercise, smoking/alcohol cessation, and mental health support, improves how patients with advanced ovarian cancer handle chemotherapy given before surgery. This matched study of 116 patients showed that those undergoing prehabilitation tolerated higher relative doses of chemotherapy and were significantly more likely to achieve complete surgical removal of all visible tumour tissue. Importantly, these benefits extended to patients aged 70 and older, a group that typically struggles with treatment tolerance. Key Findings Higher Chemo Tolerance: Patients in the prehabilitation group completed their planned chemotherapy cycles with fewer side-effect delays or dose reductions. Better Surgical Outcomes: Building physical reserve before interval surgery led to higher rates of complete cancer removal with no...
Post a Comment
Read more

Check for Vitamin D deficiency

Image
Vitamin D in Ovarian Cancer Recurrence. Study Reference: Laboratory / Translational Study   Ovarian cancer often recurs with poor outcomes, making recurrence prevention a major research focus. Emerging evidence shows that platinum chemotherapy can trigger non-stem cancer cells to convert into chemoresistant stem cells,and relapse. Vitamin D limits this conversion. Chemo treatment exacerbates vitamin D deficiency. Since   20% of Australian women are already vitamin D deficient ( a figure rising significantly in winter), routine testing and supplementation offer a safe, accessible strategy to help limit resistance and reduce recurrence risk. Key Points Driver of Relapse: Platinum chemotherapy may change cancer cells into stem-like cells, causing chemoresistance. Targeted Mechanism: Vitamin D  acts as a brake on this process, helping maintain chemotherapy sensitivity. Common Deficiency: About 1 in 5 Australian women are vitamin D deficient, with higher rates during ...
Post a Comment
Read more

Vaccines for ovarian cancer seem far off.

Image
Therapeutic Vaccines for Ovarian Cancer: Is Clinical Reality Close? Study Reference: Systematic Review / Clinical Trial Analysis   The prospect of therapeutic vaccine therapy for ovarian cancer has generated interest for decades; such vaccines function by mobilising a targeted immune response against specific tumour antigens. While platforms using DNA, mRNA, peptides, and dendritic cells have streamlined vaccine manufacturing, clinical progress remains largely exploratory. A comprehensive review of 136 registered trials shows that over 90% remain in early Phase I or II, and no therapeutic vaccine has yet demonstrated clinical efficacy in Phase III trials. Consequently, current clinical development is shifting toward combination strategies (such as targeted antibody-drug conjugates) to overcome immune suppression. Key Points Exploratory Stage: Three  decades of research show that most therapeutic vaccine trials for ovarian cancer remain limited to early safety and immunogenici...
Post a Comment
Read more